rs11895736 - LTBP1

Magnitude 2.2 · 1 study on file

Reported associations

• Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens - Unknown journal (n.d.) · Unknown authors · PubMed 34528705

  ABSTRACT: Germline variants might predict cancer progression. Bevacizumab improves overall survival (OS) in patients with advanced cancers. No biomarkers are available to identify patients that benefit from bevacizumab. A meta-analysis of genome-wide association studies (GWAS) was conducted in 1,520 patients from phase III trials (CALGB 80303, 40503, 80405, and ICON7), where bevacizumab was randomized to treatment without bevacizumab. We aimed to identify genes and SNPs associated with survival independently of bevacizumab treatment or through interaction with bevacizumab. A cause-specific Cox model was used to test the SNP-OS association in both arms combined (prognostic), and the effect of SNPs-bevacizumab interaction on OS (predictive) in each study. The SNP effects across studies were

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.